In 2006, Robert Copeland and colleagues David Pompliano and Thomas Meek published the residence time model, which accounts for the conformational dynamics of target macromolecules that affect drug binding and dissociation. During drug development initiatives, the analysis of drug-target residence times can improve efficacy, increase therapeutic windows, and reduce the risk of prematurely focusing on candidate compounds that are likely to have undesirable side effects.
Download this guide from BellBrook Labs to learn about:
- The technical background on concepts and techniques for the use of Transcreener® biochemical assays
- How to use Transcreener biochemical assays to measure drug-target residence times, complete with examples and case studies
